抑制围突触星细胞糖原利用对抑郁症类行为的影响
Turk psikiyatri dergisi = Turkish journal of psychiatry
|January 4, 2024
概括
药理上抑制天体细胞糖原利用并没有改变小鼠的焦虑类或抑郁类行为. 观察到男性的运动活动增加和女性的糖糖偏好,但与情绪变化无关.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 行为科学 行为科学
背景情况:
- 星球细胞产生乳酸盐以推动神经元活动和突触能量需求.
- 天体细胞乳酸生产中断与严重抑郁症病理生理学有关.
- 了解星体细胞能量代谢对于开发新型抑郁症治疗非常重要.
研究的目的:
- 为了研究抑制围突触性天体细胞糖原利用对焦虑和抑郁类行为的影响.
- 为了评估这些影响在雌性和雄性小鼠.
- 通过调节星细胞能量通路来探索情绪障碍的潜在治疗点.
主要方法:
- 在雌性和雄性小鼠体内注射1,4-二氧化-1,4-氨基-D-阿拉宾 (DAB),一种糖原酸化酶抑制剂,或液.
- 在注射后3天和5天进行了行为评估,包括运动活动,开放场测试,光暗箱测试,尾部悬浮测试和糖偏好测试.
主要成果:
- 在注射后3天的雄性或雌性小鼠中没有观察到显著的焦虑或抑郁类行为变化.
- 注射后五天,雄性小鼠表现出运动运动活动增加和在野外的时间增加.
- 雌性小鼠的糖糖偏好显著增加,这表明它们对糖的渴望有所改变,而不是享乐行为.
结论:
- 通过DAB抑制海马体的糖原利用并没有诱导小鼠的焦虑或抑郁类行为.
- 在男性中观察到的行为变化归因于运动活动增加,而不是焦虑.
- 雌性增加的糖糖偏好可能反映出恒常的糖渴望,这需要进一步研究下丘脑能量代谢.
相关概念视频
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...